
Cadrenal Therapeutics, Inc.
100
Cadrenal Therapeutics has initiated a formal strategic review following FDA alignment on CAD-1005's Phase 3 trial path. The company reported positive Phase 2 data for CAD-1005, announced an $8.8 million private placement, and continues to advance tecarfarin toward FDA filings. Financial challenges and strategic alternatives remain key focus areas.
- Cadrenal Therapeutics began a formal strategic review process in October 2026 following FDA alignment on the registrational path for CAD-1005's Phase 3 trial [N1].
- The company reported clinical data from its Phase 2 study of CAD-1005, showing fewer thrombotic events in the treatment group despite not meeting the primary endpoint [N3].
- Cadrenal announced an $8.8 million private placement in July 2026 to support operations and development [N4].
- The company continues to advance tecarfarin toward FDA Rare Pediatric Disease Designation filings and potential Phase 3 trials [N8].
- Cadrenal's broader pipeline and strategic initiatives remain under evaluation amid financial constraints and ongoing efforts to secure partnerships or financing [N1][N3][N4].
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The company acquired a 12-lipoxygenase (12-LOX) platform in December 2025, shifting its primary focus to CAD-1005, a first-in-class selective 12-LOX inhibitor for treating heparin-induced thrombocytopenia (HIT). CAD-1005 has orphan drug and Fast Track designations from the FDA and orphan designation from the EMA. It has completed Phase 1 and Phase 2 clinical trials, with the Phase 2 trial showing fewer thrombotic events in the treatment group despite not meeting the primary endpoint. The company completed an End-of-Phase 2 meeting with the FDA in March 2026, clarifying a potential Phase 3 trial path, subject to FDA review and financing. The broader pipeline includes tecarfarin, an oral vitamin K antagonist designed for chronic anticoagulation in patients with kidney dysfunction or LVADs, and frunexian, a Phase 2-ready intravenous Factor XIa inhibitor for acute care settings. As of September 30, 2026, Cadrenal had $3.06 million in cash and equivalents, a current ratio of 6.26, and reported a net loss of $1.25 million for the quarter. The company is pursuing additional financing and strategic alternatives, including a formal strategic review initiated in October 2026.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing novel therapies for immune and thrombotic conditions. Its lead candidate, CAD-1005, is a selective 12-LOX inhibitor targeting heparin-induced thrombocytopenia (HIT), with orphan drug and Fast Track designations from the FDA and orphan designation from the EMA. CAD-1005 has completed Phase 1 and Phase 2 clinical trials; the Phase 2 trial did not meet its primary endpoint but showed fewer thrombotic events in the treatment group. The company completed an End-of-Phase 2 meeting with the FDA in March 2026, clarifying a potential Phase 3 trial path, subject to FDA review and financing. The broader pipeline includes tecarfarin, an oral vitamin K antagonist with orphan drug and Fast Track designations, evaluated in over 1,000 patients, and frunexian, a Phase 2-ready intravenous Factor XIa inhibitor for acute care. As of September 30, 2026, Cadrenal had $3.06 million in cash and equivalents, a current ratio of 6.26, and reported a net loss of $1.25 million for the quarter. The company expects its cash to be insufficient for the next twelve months and is pursuing additional financing and strategic alternatives, including a formal strategic review initiated in October 2026. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Cadrenal's lead candidate CAD-1005 targets a serious unmet medical need in HIT with a novel mechanism of action and regulatory designations that could facilitate development. Positive Phase 1 and Phase 2 data, including fewer thrombotic events in treated patients, support its potential. The company's broader pipeline with tecarfarin and frunexian addresses additional anticoagulation needs with differentiated profiles. The ongoing strategic review and efforts to secure partnerships or financing could enable advancement of clinical programs and commercialization. Strong liquidity ratios as of September 2026 provide some operational runway.
Cadrenal faces significant financial constraints with limited cash and an accumulated deficit, raising substantial doubt about its ability to continue as a going concern without additional financing. The Phase 2 trial of CAD-1005 did not meet its primary endpoint, and the Phase 3 trial is contingent on FDA review and securing sufficient funding. The company is subject to Nasdaq listing risks and potential dilution from outstanding warrants and PIPE transaction terms. The strategic review process may not result in a transaction or value creation, and failure to secure partnerships or financing could impair clinical development and operations.
Cadrenal Therapeutics' moat is based on its proprietary 12-LOX inhibitor platform, with CAD-1005 representing a novel therapeutic approach targeting the underlying immune-mediated pathophysiology of HIT, a condition with limited treatment options. The company holds orphan drug and Fast Track designations from regulatory agencies, which may provide regulatory and market advantages. Its pipeline includes differentiated assets such as tecarfarin, designed to overcome limitations of existing vitamin K antagonists, and frunexian, targeting acute care settings. The company's acquisition of exclusive licenses and intellectual property related to 12-LOX inhibitors further supports its competitive position. However, the company faces challenges related to clinical development, financing, and market adoption in a competitive biopharmaceutical landscape.
• Liquidity and Going Concern Risk: The company had approximately $3.06 million in cash as of September 30, 2026, which management believes is insufficient to meet cash requirements for the next twelve months, raising substantial doubt about its ability to continue as a going concern without additional financing [S2].
• Clinical Development Risk: CAD-1005 failed to meet the primary endpoint in its Phase 2 trial, and the Phase 3 pivotal trial is subject to FDA review and sufficient financing, creating uncertainty around clinical advancement [S1].
• Regulatory and Market Access Risk: Maintaining orphan drug and Fast Track designations is critical; failure to obtain additional regulatory approvals or designations could impact development and commercialization prospects [S1].
• Nasdaq Listing Compliance Risk: The company faces risks related to maintaining minimum stockholders' equity and market value of listed securities requirements, which could lead to delisting [S2].
• Financing and Dilution Risk: Outstanding warrants and PIPE transaction restrictions may limit the company's ability to raise capital on favorable terms and could cause dilution to existing shareholders [S2].
• Strategic Transaction Risk: The ongoing strategic review may not result in a transaction or value creation, and failure to secure partnerships or out-licensing agreements could impair the company's ability to advance its pipeline or continue operations [N1][S2].
Business trends: Focus on advancing CAD-1005 for HIT with regulatory designations and expanding pipeline with tecarfarin and frunexian amid financial constraints.
Execution milestones: Completion of FDA Phase 3 trial protocol review, securing additional financing, and potential strategic partnerships or transactions.
Key risks: Liquidity constraints raising going concern doubts, clinical trial uncertainties, Nasdaq listing compliance risks, and dependence on successful strategic alternatives.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Cadrenal Therapeutics is a late-stage biopharmaceutical company focused on immune and thrombotic conditions, with lead candidate CAD-1005 targeting heparin-induced thrombocytopenia (HIT) [S1].
- CAD-1005 is a selective 12-LOX inhibitor with orphan drug and Fast Track designations from FDA and orphan designation from EMA [S1].
- CAD-1005 has completed Phase 1 and Phase 2 trials; Phase 2 did not meet primary endpoint but showed fewer thrombotic events in treated group [S1].
- Company completed End-of-Phase 2 FDA meeting in March 2026, clarifying Phase 3 trial path, subject to FDA review and financing [S1].
- Pipeline includes tecarfarin, an oral vitamin K antagonist with orphan drug and Fast Track designations for specific indications, evaluated in over 1,000 patients [S1].
- Frunexian is a Phase 2-ready intravenous Factor XIa inhibitor for acute care settings [S1].
- As of September 30, 2026, company had $3.06 million cash, $3.45 million current assets, $0.55 million current liabilities, current ratio 6.26, cash ratio 5.54 [S2].
- Reported net loss of $1.25 million and EPS of -$0.31 for Q3 2026; accumulated deficit approx. $46 million as of Sept 30, 2026 [S2].
- Company expects cash insufficient for next 12 months and is pursuing additional financing and strategic alternatives [S2].
- Board initiated strategic review in October 2026 to evaluate licensing, asset sales, partnerships, mergers, or other transactions [N1][S2].
- Company faces risks related to Nasdaq listing compliance and potential dilution from warrants and PIPE transaction [S2].
Generated 2026-11-17
- S1 | 2026-03-31 | 10-K
- S2 | 2026-11-16 | 10-Q
- N1 | 2026-10-07 | www.nasdaq.com | Cadrenal Therapeutics Begins Strategic Review Following FDA Alignment On CAD-1005 | https://www.nasdaq.com/articles/cadrenal-therapeutics-begins-strategic-review-following-fda-alignment-cad-1005
- N2 | 2026-07-18 | www.nasdaq.com | Weekly Buzz: NVS, MRK Win FDA Nod; LLY Snaps Up ATAI; MANE Shines On Hair Loss Data | https://www.nasdaq.com/articles/weekly-buzz-nvs-mrk-win-fda-nod-lly-snaps-atai-mane-shines-hair-loss-data
- N3 | 2026-07-13 | www.nasdaq.com | Cadrenal Therapeutics Reports Clinical Data From Phase 2 Study Of CAD-1005 | https://www.nasdaq.com/articles/cadrenal-therapeutics-reports-clinical-data-phase-2-study-cad-1005
- N4 | 2026-07-01 | www.nasdaq.com | Cadrenal Therapeutics Announces $8.8 Million Private Placement | https://www.nasdaq.com/articles/cadrenal-therapeutics-announces-88-million-private-placement
- N5 | 2025-11-08 | www.nasdaq.com | Cadrenal Therapeutics, Inc. | https://www.nasdaq.com/articles/cadrenal-therapeutics-inc-0
- N6 | 2025-11-08 | www.nasdaq.com | Cadrenal Therapeutics, Inc. | https://www.nasdaq.com/articles/cadrenal-therapeutics-inc
- N7 | 2025-05-07 | www.nasdaq.com | CADRENAL THERAPEUTICS Earnings Preview: Recent $CVKD Insider Trading, Hedge Fund Activity, and More | https://www.nasdaq.com/articles/cadrenal-therapeutics-earnings-preview-recent-cvkd-insider-trading-hedge-fund-activity-and
- N8 | 2024-12-31 | www.nasdaq.com | Cadrenal Therapeutics to initiate Phase 3 clinical trial for tecarfarin in 2025 | https://www.nasdaq.com/articles/cadrenal-therapeutics-initiate-phase-3-clinical-trial-tecarfarin-2025
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


